SlideShare a Scribd company logo
MICROTUBULE
INHIBITORS
1 BENZIMIDAZOLES
 are in use for the treatment of helminthic
infections
 have a broad range of activity against many
nematode and cestode parasites, including
cutaneous larva migrans, trichinosis,
disseminated strongyloidiasis, and visceral
larva migrans
 considered as the drug of choice for Fasciola
hepatica therapy
1.1 Thiabendazole
 inhibits fumarate reductase and electron
transport–associated phosphorylation in helminths
 Interference with ATP generation decreases
glucose uptake and affects the energy available
for metabolism
 This inhibits microtubule assembly, which is
important in a number of helminth cellular
processes, such as mitosis, transport, and motility.
 shows a broad spectrum of activity against
different nematodas lumbricoides, N. americanus,
A. duodenale, E. vermicularis, S. stercoralis, and
Trichuris trichiura
Adverse drug reactions
 Anorexia
 nausea
 vomiting
 Drowsiness
 vertigo occur in upto one-third of patients
 Diarrhea, pruritus, rash, hallucinations, crystalluria,
and leukopenia are less common
 shock, hyperglycemia, lymphadenopathy, and
Stevens-Johnson syndrome are rare.
 Some patients report that their urine smells like
asparagus, a reaction related to excretion of the
metabolite asparagine.
1.2 Albendazole
 cytoplasmic microtubular degeneration, which in
turn impairs vital cellular processes and leads to
parasite death
 also inhibits helminth-specific ATP generation by
fumarate reductase
 given orally and is poorly and variably absorbed
(5%) because of its poor water solubility
 Oral bioavailability is increased as much as five
times when the drug is given with a fatty meal
instead of on an empty stomach
 Has broad spectrum of activity against intestinal
nematodes and cestodes, as well as the liver
flukes
Adverse drug reactions
2 Vinca Alkaloids (Vincristine, Vinblastine, and
Vinorelbine)
 alkaloids bind avidly to tubulin, a class of proteins that
form the mitotic spindle during cell division
 regarded as phase specific in the cell cycle, some
mammalian cells are most vulnerable in the late S-
phase
 Both vincristine and vinblastine are extensively bound
to tissues, and only small amounts of the drug are
distributed to the brain or CSF with nearly similar
pharmacokinetics
 Vincristine is an important component of the curative
combination chemotherapy for acute lymphoblastic
leukemia, Hodgkin’s disease (the MOPP regimen),
and non-Hodgkin’s lymphomas
Cont …
 Vinorelbine is particularly useful in the
treatment of advanced non–small cell lung
cancer and can be administered alone or in
combination with cisplatinIt
 thought to interfere with mitosis in dividing
cells through a relatively specific action on
mitotic microtubules.
Adverse drug reaction
 Neurological toxicity
 bone marrow toxicity
 Severe leukopenia
 potent local blistering agents and will produce
tissue necrosis if extravasated.
3 Taxanes (Paclitaxel)
 highly complex, organic compound isolated from
the bark of the Pacific yewtree
 binds to tubulin dimers and microtubulin filaments,
promoting the assembly of filaments and
preventing their depolymerization
 increase in the stability of microfilaments results in
disruption of mitosis and cytotoxicity and disrupts
other normal microtubular functions, such as
axonal transport in nerve fiber
 among the most active of all anticancer drugs,
with significant efficacy against carcinomas of the
breast, ovary, lung, head, and neck
Adverse drug reaction
 Myelosuppression
 Alopecia
 Most patients have mild numbness and
tingling of the fingers and toes
 Mild muscle and joint aching
 Nausea is usually mild or absent
 Severe hypersensitivity reactions may occur
 Cardiovascular side effects, consisting of mild
hypotension and bradycardia, have been
noted
Monoclonal antibody
Palivizumab (Synagis)
 is a humanized monoclonal antibody directed against
the highly conserved antigenic site of the F protein on
the surface of RSV
 contains 95% human and 5% murine antibody
sequences and tends to have little immunogenicity in
humans
 is composed of the human framework region of the
IgG-1 -chain joined to the antigen-binding regions of a
mouse monoclonal antibody
 neutralizes RSV and inhibits its ability to fuse with
host cell membranes. Resistant strains of RSV have
been derived in vitro but have not been found in
clinical isolates to date.
Cont …
 administered prophylactically as a monthly
intramuscular injection prior to and during RSV
season
 half-life of palivizumab is approximately 20 days
 used to prevent serious lower respiratory tract
infection due to RSV
 only in high-risk children who are younger than 24
months of age and have bronchopulmonary
dysplasia or chronic lung disease that required
treatment in the previous 6 months
 is also indicated for premature infants (less than
32 weeks’ gestation)
Adverse drug reaction
 Serious adverse reactions are rare
 Mild erythema and pain may occur at the
injection site
 Although no anaphylactoid reactions have
been reported to date, the possibility of this
reaction exists because palivizumab is a
protein,
Monoclonal antibody drug for
Immunomodulating(Muromonab-(CD3))
 is a mouse monoclonal antibody that is a purified IgG
 used for the prevention of acute allograft rejection in kidney
and hepatic transplants and as prophylaxis in cardiac
transplantation
 also used to deplete T cells in marrow from donors before
bone marrow transplantation.
 alters the cell-mediated immune response by binding to the
CD3 (cluster of differentiation antigen, T3) glycoprotein on T.
 Within minutes of injection, total circulating T cells are rapidly
depleted from the blood
 later reappear devoid of CD3 and antigen recognition
complexes.
Adverse side effects
 include fever
 pulmonary edema,
 Vomiting
 Headache
 anaphylaxis
Monoclonal antibody drug for Gastrointestinal
Disorders(Infliximab)
 TNF-is an inflammatory cytokine thought to have a
contributory role in producing chronic inflammation in
various diseases, including Crohn’s disease and
rheumatoid arthritis
 is a mouse–human chimeric monoclonal neutralizing
antibody to human TNF- and is considered a
biological drug
 Specific indications are for the reduction of signs and
symptoms in patients with moderately to severely
active Crohn’s disease) and fistulizing Crohn’s
disease
 Responses occur within 2 weeks of an infusion,
The most common side effects
 include rash
 low blood pressure
 chills, and chest pain these symptoms are
generally temporary and often respond to a
decrease in infusion rate
 Another side effect is increased risk of
infections
 Fatal cases of tuberculosis have been
reported following infliximab therapy
 increased risk of lymphoma

More Related Content

Similar to pharma ppt.pptx

Anti mycobacterial drugs
Anti mycobacterial drugsAnti mycobacterial drugs
Anti mycobacterial drugs
Nasir Khan
 
Anti rheumatoid drugs
Anti rheumatoid drugsAnti rheumatoid drugs
Anti rheumatoid drugs
SweetySharma43
 
Anti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdfAnti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdf
Koppala RVS Chaitanya
 
Vaccination in CKD patients
Vaccination in CKD patients Vaccination in CKD patients
Vaccination in CKD patients
Chetan Somani
 
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
CCRMHZN
 
Treatment of resistant & relapsing polymyositis dm
Treatment of  resistant & relapsing polymyositis dmTreatment of  resistant & relapsing polymyositis dm
Treatment of resistant & relapsing polymyositis dm
Faculty of Medicine, Ain Shams University
 
Immunomodulators and immunostimulants
Immunomodulators and immunostimulantsImmunomodulators and immunostimulants
Immunomodulators and immunostimulants
Rahul k
 
Clinical Pharmacology of the Anthelmintic Drugs.ppt
Clinical Pharmacology of the Anthelmintic Drugs.pptClinical Pharmacology of the Anthelmintic Drugs.ppt
Clinical Pharmacology of the Anthelmintic Drugs.ppt
NorhanKhaled15
 
Immunomodulators
ImmunomodulatorsImmunomodulators
Immunomodulatorskinjan92
 
Immunosuppressive agents in ophthalmology
Immunosuppressive agents in ophthalmologyImmunosuppressive agents in ophthalmology
Immunosuppressive agents in ophthalmology
Tina Chandar
 
Antihelminthiasis.pptx
Antihelminthiasis.pptxAntihelminthiasis.pptx
Antihelminthiasis.pptx
Anant Khot
 
Introduction of immunity and immunosuppressed drugs
Introduction of immunity  and immunosuppressed drugsIntroduction of immunity  and immunosuppressed drugs
Introduction of immunity and immunosuppressed drugs
Abdikadir Daahir
 
IMMUNOSUPPRESSANT DRUGS
IMMUNOSUPPRESSANT DRUGSIMMUNOSUPPRESSANT DRUGS
IMMUNOSUPPRESSANT DRUGS
paramesh Researcher
 
Lupus nephritis Management
Lupus nephritis ManagementLupus nephritis Management
Lupus nephritis Management
SRM Medical College
 
Immunosuppressive drugs
Immunosuppressive drugsImmunosuppressive drugs
Immunosuppressive drugs
Ayatollah Abdel-sattar
 
IMMUNOMODULATORS.ppt
IMMUNOMODULATORS.pptIMMUNOMODULATORS.ppt
IMMUNOMODULATORS.ppt
shekharkapoor18
 
Lupus 2.0
Lupus 2.0Lupus 2.0
Anti tumor necrosis factor therapy
Anti tumor necrosis factor therapyAnti tumor necrosis factor therapy
Anti tumor necrosis factor therapy
Domina Petric
 
Immunosuppressants drugs and their mechanism of action in organ transplantati...
Immunosuppressants drugs and their mechanism of action in organ transplantati...Immunosuppressants drugs and their mechanism of action in organ transplantati...
Immunosuppressants drugs and their mechanism of action in organ transplantati...
Sreedhar Reddy
 

Similar to pharma ppt.pptx (20)

Anti mycobacterial drugs
Anti mycobacterial drugsAnti mycobacterial drugs
Anti mycobacterial drugs
 
Anti rheumatoid drugs
Anti rheumatoid drugsAnti rheumatoid drugs
Anti rheumatoid drugs
 
Anti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdfAnti Rheumatic drugs.pdf
Anti Rheumatic drugs.pdf
 
Vaccination in CKD patients
Vaccination in CKD patients Vaccination in CKD patients
Vaccination in CKD patients
 
Antiviral drugs
Antiviral drugsAntiviral drugs
Antiviral drugs
 
Treatment of resistant & relapsing polymyositis dm
Treatment of  resistant & relapsing polymyositis dmTreatment of  resistant & relapsing polymyositis dm
Treatment of resistant & relapsing polymyositis dm
 
Immunomodulators and immunostimulants
Immunomodulators and immunostimulantsImmunomodulators and immunostimulants
Immunomodulators and immunostimulants
 
Clinical Pharmacology of the Anthelmintic Drugs.ppt
Clinical Pharmacology of the Anthelmintic Drugs.pptClinical Pharmacology of the Anthelmintic Drugs.ppt
Clinical Pharmacology of the Anthelmintic Drugs.ppt
 
Immunomodulators
ImmunomodulatorsImmunomodulators
Immunomodulators
 
Immunosuppressive agents in ophthalmology
Immunosuppressive agents in ophthalmologyImmunosuppressive agents in ophthalmology
Immunosuppressive agents in ophthalmology
 
Antihelminthiasis.pptx
Antihelminthiasis.pptxAntihelminthiasis.pptx
Antihelminthiasis.pptx
 
Introduction of immunity and immunosuppressed drugs
Introduction of immunity  and immunosuppressed drugsIntroduction of immunity  and immunosuppressed drugs
Introduction of immunity and immunosuppressed drugs
 
IMMUNOSUPPRESSANT DRUGS
IMMUNOSUPPRESSANT DRUGSIMMUNOSUPPRESSANT DRUGS
IMMUNOSUPPRESSANT DRUGS
 
Lupus nephritis Management
Lupus nephritis ManagementLupus nephritis Management
Lupus nephritis Management
 
Renal transplant
Renal transplant Renal transplant
Renal transplant
 
Immunosuppressive drugs
Immunosuppressive drugsImmunosuppressive drugs
Immunosuppressive drugs
 
IMMUNOMODULATORS.ppt
IMMUNOMODULATORS.pptIMMUNOMODULATORS.ppt
IMMUNOMODULATORS.ppt
 
Lupus 2.0
Lupus 2.0Lupus 2.0
Lupus 2.0
 
Anti tumor necrosis factor therapy
Anti tumor necrosis factor therapyAnti tumor necrosis factor therapy
Anti tumor necrosis factor therapy
 
Immunosuppressants drugs and their mechanism of action in organ transplantati...
Immunosuppressants drugs and their mechanism of action in organ transplantati...Immunosuppressants drugs and their mechanism of action in organ transplantati...
Immunosuppressants drugs and their mechanism of action in organ transplantati...
 

Recently uploaded

The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
JEE1_This_section_contains_FOUR_ questions
JEE1_This_section_contains_FOUR_ questionsJEE1_This_section_contains_FOUR_ questions
JEE1_This_section_contains_FOUR_ questions
ShivajiThube2
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Scholarhat
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
TechSoup
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
David Douglas School District
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Dr. Vinod Kumar Kanvaria
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 

Recently uploaded (20)

The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
JEE1_This_section_contains_FOUR_ questions
JEE1_This_section_contains_FOUR_ questionsJEE1_This_section_contains_FOUR_ questions
JEE1_This_section_contains_FOUR_ questions
 
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHatAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat  Leveraging AI for Diversity, Equity, and InclusionExecutive Directors Chat  Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School DistrictPride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 

pharma ppt.pptx

  • 2. 1 BENZIMIDAZOLES  are in use for the treatment of helminthic infections  have a broad range of activity against many nematode and cestode parasites, including cutaneous larva migrans, trichinosis, disseminated strongyloidiasis, and visceral larva migrans  considered as the drug of choice for Fasciola hepatica therapy
  • 3. 1.1 Thiabendazole  inhibits fumarate reductase and electron transport–associated phosphorylation in helminths  Interference with ATP generation decreases glucose uptake and affects the energy available for metabolism  This inhibits microtubule assembly, which is important in a number of helminth cellular processes, such as mitosis, transport, and motility.  shows a broad spectrum of activity against different nematodas lumbricoides, N. americanus, A. duodenale, E. vermicularis, S. stercoralis, and Trichuris trichiura
  • 4. Adverse drug reactions  Anorexia  nausea  vomiting  Drowsiness  vertigo occur in upto one-third of patients  Diarrhea, pruritus, rash, hallucinations, crystalluria, and leukopenia are less common  shock, hyperglycemia, lymphadenopathy, and Stevens-Johnson syndrome are rare.  Some patients report that their urine smells like asparagus, a reaction related to excretion of the metabolite asparagine.
  • 5. 1.2 Albendazole  cytoplasmic microtubular degeneration, which in turn impairs vital cellular processes and leads to parasite death  also inhibits helminth-specific ATP generation by fumarate reductase  given orally and is poorly and variably absorbed (5%) because of its poor water solubility  Oral bioavailability is increased as much as five times when the drug is given with a fatty meal instead of on an empty stomach  Has broad spectrum of activity against intestinal nematodes and cestodes, as well as the liver flukes
  • 7. 2 Vinca Alkaloids (Vincristine, Vinblastine, and Vinorelbine)  alkaloids bind avidly to tubulin, a class of proteins that form the mitotic spindle during cell division  regarded as phase specific in the cell cycle, some mammalian cells are most vulnerable in the late S- phase  Both vincristine and vinblastine are extensively bound to tissues, and only small amounts of the drug are distributed to the brain or CSF with nearly similar pharmacokinetics  Vincristine is an important component of the curative combination chemotherapy for acute lymphoblastic leukemia, Hodgkin’s disease (the MOPP regimen), and non-Hodgkin’s lymphomas
  • 8. Cont …  Vinorelbine is particularly useful in the treatment of advanced non–small cell lung cancer and can be administered alone or in combination with cisplatinIt  thought to interfere with mitosis in dividing cells through a relatively specific action on mitotic microtubules.
  • 9. Adverse drug reaction  Neurological toxicity  bone marrow toxicity  Severe leukopenia  potent local blistering agents and will produce tissue necrosis if extravasated.
  • 10. 3 Taxanes (Paclitaxel)  highly complex, organic compound isolated from the bark of the Pacific yewtree  binds to tubulin dimers and microtubulin filaments, promoting the assembly of filaments and preventing their depolymerization  increase in the stability of microfilaments results in disruption of mitosis and cytotoxicity and disrupts other normal microtubular functions, such as axonal transport in nerve fiber  among the most active of all anticancer drugs, with significant efficacy against carcinomas of the breast, ovary, lung, head, and neck
  • 11. Adverse drug reaction  Myelosuppression  Alopecia  Most patients have mild numbness and tingling of the fingers and toes  Mild muscle and joint aching  Nausea is usually mild or absent  Severe hypersensitivity reactions may occur  Cardiovascular side effects, consisting of mild hypotension and bradycardia, have been noted
  • 13. Palivizumab (Synagis)  is a humanized monoclonal antibody directed against the highly conserved antigenic site of the F protein on the surface of RSV  contains 95% human and 5% murine antibody sequences and tends to have little immunogenicity in humans  is composed of the human framework region of the IgG-1 -chain joined to the antigen-binding regions of a mouse monoclonal antibody  neutralizes RSV and inhibits its ability to fuse with host cell membranes. Resistant strains of RSV have been derived in vitro but have not been found in clinical isolates to date.
  • 14. Cont …  administered prophylactically as a monthly intramuscular injection prior to and during RSV season  half-life of palivizumab is approximately 20 days  used to prevent serious lower respiratory tract infection due to RSV  only in high-risk children who are younger than 24 months of age and have bronchopulmonary dysplasia or chronic lung disease that required treatment in the previous 6 months  is also indicated for premature infants (less than 32 weeks’ gestation)
  • 15. Adverse drug reaction  Serious adverse reactions are rare  Mild erythema and pain may occur at the injection site  Although no anaphylactoid reactions have been reported to date, the possibility of this reaction exists because palivizumab is a protein,
  • 16. Monoclonal antibody drug for Immunomodulating(Muromonab-(CD3))  is a mouse monoclonal antibody that is a purified IgG  used for the prevention of acute allograft rejection in kidney and hepatic transplants and as prophylaxis in cardiac transplantation  also used to deplete T cells in marrow from donors before bone marrow transplantation.  alters the cell-mediated immune response by binding to the CD3 (cluster of differentiation antigen, T3) glycoprotein on T.  Within minutes of injection, total circulating T cells are rapidly depleted from the blood  later reappear devoid of CD3 and antigen recognition complexes.
  • 17. Adverse side effects  include fever  pulmonary edema,  Vomiting  Headache  anaphylaxis
  • 18. Monoclonal antibody drug for Gastrointestinal Disorders(Infliximab)  TNF-is an inflammatory cytokine thought to have a contributory role in producing chronic inflammation in various diseases, including Crohn’s disease and rheumatoid arthritis  is a mouse–human chimeric monoclonal neutralizing antibody to human TNF- and is considered a biological drug  Specific indications are for the reduction of signs and symptoms in patients with moderately to severely active Crohn’s disease) and fistulizing Crohn’s disease  Responses occur within 2 weeks of an infusion,
  • 19. The most common side effects  include rash  low blood pressure  chills, and chest pain these symptoms are generally temporary and often respond to a decrease in infusion rate  Another side effect is increased risk of infections  Fatal cases of tuberculosis have been reported following infliximab therapy  increased risk of lymphoma